Elliott Statement on Aspen Technology, Inc.

2025-02-10 Elliott Investment Management L.P. HaiPress

WEST PALM BEACH,Fla.,Feb. 7,2025 -- Elliott Investment Management L.P. ("Elliott"),which manages funds that together have an investment of more than $1.5 billion in Aspen Technology,Inc. (NASDAQ: AZPN) (the "Company" or "AspenTech"),today issued the following statement regarding the Company's recently announced agreement with Emerson Electric Co. (NYSE: EMR) ("Emerson"):

"As the largest minority investor in AspenTech,we disagree with the Company's decision to support a $265.00 per share tender offer by its majority stockholder,Emerson,to acquire the AspenTech shares it does not already own. Emerson's offer is highly opportunistic and substantially undervalues the Company. Elliott has no intention of tendering its shares at the current price."

About Elliott

Elliott Investment Management L.P. (together with its affiliates,"Elliott") manages approximately$69.7 billionof assets as ofJune 30,2024. Founded in 1977,it is one of the oldest funds under continuous management. The Elliott funds' investors include pension plans,sovereign wealth funds,endowments,foundations,funds-of-funds,high net worth individuals and families,and employees of the firm.

Media Contact


Alice Best


Elliott Advisors (UK) Limited


T: +44 203 009 1715


abest@elliottadvisors.co.uk
Disclaimer: This article is reproduced from other media. The purpose of reprinting is to convey more information. It does not mean that this website agrees with its views and is responsible for its authenticity, and does not bear any legal responsibility. All resources on this site are collected on the Internet. The purpose of sharing is for everyone's learning and reference only. If there is copyright or intellectual property infringement, please leave us a message.

Newest

1Cangxi County Holds 2026 New Year's Cultural Performance for the Public

Cangxi County Holds 2026 New Year's Cultural Performance for the Public

2The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

3The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

4Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

5Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

6Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

©copyright 2009-2020 Singapore Info Map